SVNT Financial Facts
Research and development: 4.15MSelling, general and administrative: 14.32M
See Full Income Statement
Accounts receivable, net: 6.82M
Total liabilities and stockholders' equity: 56.14M
See Full Balance Sheet
Savient Pharmaceuticals, Inc. (SVNT) Earnings
|
Expand Research on SVNT
Next EPS Date | N/A | EPS Growth Rate | N/A |
---|---|---|---|
Average EPS % Beat Rate | -7.0% | Revenue Growth Rate | N/A |
Average % Move 1-Wk after EPS | -4.8% | Normal Earnings Time | Before Open |
Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
---|---|---|---|---|---|---|---|---|---|---|---|
11/8/12 | Q312 | -$0.56 | -$0.48 | -$0.08 | $4.9M | $5.85M | N/A | Details | |||
5/9/12 | Q112 | -$0.49 | -$0.46 | -$0.03 | $3.5M | $4.59M | N/A | Details | |||
2/27/12 | Q411 | -$0.44 | -$0.38 | -$0.06 | $3.71M | $3.51M | N/A | Details | |||
8/4/11 | Q211 | -$0.43 | -$0.30 | -$0.13 | $2M | $2.77M | N/A | Details | |||
3/19/13 | Q412 | -$0.39 | -$0.44 | +$0.05 | $4.95M | $6.18M | N/A | Details | |||
11/3/11 | Q311 | -$0.39 | -$0.40 | +$0.01 | $2.58M | $3.17M | N/A | Details | |||
8/7/13 | Q213 | -$0.35 | -$0.31 | -$0.04 | $6.7M | $5.84M | N/A | Details | |||
5/15/13 | Q113 | -$0.34 | -$0.31 | -$0.03 | $4.7M | $5.65M | N/A | Details |